USD10
MIRM Anteile
Über Mirum PharmaceuticalsMirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
USD10
MIRM Anteile
Über Mirum PharmaceuticalsMirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Statistiken
TRADINGFENSTER
Geschlossen
ÖFFNET AM
23. März at 13:30 GMT+0
MARKTKAPITALISIERUNG
5,34 Mrd. $
ERÖFFNUNGSPREIS
Nicht genügend Daten
TIEF (1 J)
36,88 $
HOCH (1 J)
109,28 $
TIEF (24 STD.)
Nicht genügend Daten
HOCH (24 STD.)
Nicht genügend Daten
VOLUMEN (24 STD.)
Nicht genügend Daten
Kursverlauf
Time | Price | Change |
|---|---|---|
Heute | Nicht genügend Daten | Nicht genügend Daten |
1 Tag | 88,51 $ | 0,00 % |
1 Woche | 90,82 $ | |
1 Monat | 105,16 $ | |
1 Jahr | 47,02 $ |